# Joint pain, muscle pain, cramps and raised creatine kinase on anticancer drugs

Source: https://onco.cc/protocols/joint-and-muscle-pain-on-anticancer-drugs/  
OnCo record `joint-and-muscle-pain-on-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Many cancer drugs cause aching joints or muscles: hormone tablets for breast cancer, paclitaxel, ibrutinib and others. Tell your team rather than putting up with it. Exercise, painkillers, acupuncture or a change of drug or dose may help. On some targeted drugs, muscle pain with weakness or dark urine needs a call to your team straight away.

## Summary

Joint and muscle symptoms are among the commonest side effects of several unrelated drug groups, and the guidance is thin and differs by drug. The reader's own team's protocol comes first.

Aromatase inhibitors. In the US letrozole label arthralgia was reported by 25.2% on letrozole against 20.4% on tamoxifen, and in the US exemestane label by 15% against 9%; the duloxetine trial's authors say about half of patients develop bothersome symptoms and 20% to 30% stop treatment early. SIO-ASCO (2022, read as an abstract) says acupuncture should be recommended. The two Cochrane reviews are less confident: the exercise review (seven studies, 400 women) found no clear evidence of benefit for these symptoms but says exercise needs to be part of routine care, and the systemic therapy review (17 studies, 2034 women) could make no definitive recommendation. Single trials: exercise (HOPE; worst joint pain fell by 1.6 points against a 0.2-point rise at 12 months), duloxetine (SWOG S1202, part-funded by Lilly; average pain 0.82 points lower than placebo by 12 weeks, with more side effects) and acupuncture (SWOG S1200; a significant reduction of uncertain clinical importance). After a switch to a second aromatase inhibitor, 38.6% of 83 women stayed on it in one study and 71.5% of 179 at 6 months in another.

Paclitaxel and nab-paclitaxel. Aches come two or three days after a dose and resolve within a few days (US paclitaxel label: 60% of patients, 8% severe; the NCI summary says 10% to 20%, starting after 1 to 2 days and lasting a median of 4 to 5 days). No preventive or treatment standard exists; simple painkillers, then opioids as needed, were used in the cohort study.

Ibrutinib. Two expert papers differ: one favours observation and supportive care for grade 1 to 2, considering a dose reduction when daily activities are affected and holding for grade 3; the other suggests paracetamol or short pulses of prednisone while ibrutinib continues at the full dose, avoiding ibuprofen-type drugs if possible because of bleeding, and holding for up to a week then reducing one level if the pain cannot be tolerated. Both mention a change to another BTK inhibitor.

Imatinib cramps: monitor and correct electrolytes; otherwise symptomatic relief only (ELN 2016).

Creatine kinase. Binimetinib, cobimetinib and avutometinib with defactinib carry rhabdomyolysis warnings with CK monitoring and hold rules. For binimetinib the US and EU documents differ on when to withhold; for cobimetinib they differ mainly on how often to test and on the terms for restarting; no EU document was found for avutometinib with defactinib. They are set out under variants. Encorafenib and vemurafenib joint pain falls under each label's general rule for adverse reactions. Rhabdomyolysis itself, and muscle or joint inflammation from checkpoint inhibitors, are outside this page.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: aromatase inhibitor arthralgia; aromatase inhibitor musculoskeletal symptoms; AIMSS; joint pain on letrozole; joint pain on anastrozole; arthralgia on ibrutinib; paclitaxel acute pain syndrome; taxane aches; myalgia on chemotherapy; muscle cramps on imatinib; raised CK on a MEK inhibitor; raised CPK on cancer treatment

## Connected records

- protocols: [Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management](https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/), [Bone health on aromatase inhibitors, ovarian suppression and androgen deprivation therapy](https://onco.cc/protocols/bone-health-on-hormone-therapy/), [Chemotherapy nerve damage (peripheral neuropathy): assessment, dose changes and prevention](https://onco.cc/protocols/chemotherapy-induced-peripheral-neuropathy-assessment-and-prevention/), [Chronic pain in cancer survivors: assessment, non-opioid treatment first and careful opioid use](https://onco.cc/protocols/chronic-pain-in-cancer-survivors/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Joint, muscle and other rheumatic side effects of checkpoint inhibitors](https://onco.cc/protocols/irae-rheumatological/)
- drugs: [Anastrozole](https://onco.cc/drugs/anastrozole/), [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/), [Binimetinib](https://onco.cc/drugs/binimetinib/), [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Duloxetine](https://onco.cc/drugs/duloxetine/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Exemestane](https://onco.cc/drugs/exemestane/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Imatinib](https://onco.cc/drugs/imatinib/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/), [Vimseltinib](https://onco.cc/drugs/vimseltinib/)
- technologies: [Acupuncture for aromatase-inhibitor joint pain](https://onco.cc/technologies/acupuncture-aromatase-inhibitor-arthralgia/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/)
- terms: [Aromatase inhibitor](https://onco.cc/terms/aromatase-inhibitor/), [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Taxanes (paclitaxel, docetaxel, nab-paclitaxel)](https://onco.cc/terms/taxane/)

---
JSON: https://onco.cc/api/v1/entities/joint-and-muscle-pain-on-anticancer-drugs.json